{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:33:41Z","timestamp":1793183621852,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006363","name":"Bolyai Foundation","doi-asserted-by":"publisher","award":["BO\/00598\/19\/5"],"award-info":[{"award-number":["BO\/00598\/19\/5"]}],"id":[{"id":"10.13039\/501100006363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010686","name":"H2020 European Institute of Innovation and Technology","doi-asserted-by":"publisher","award":["739593"],"award-info":[{"award-number":["739593"]}],"id":[{"id":"10.13039\/100010686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["TKP2021-EGA-28"],"award-info":[{"award-number":["TKP2021-EGA-28"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["EK\\u00D6P-24-4-SZTE-368"],"award-info":[{"award-number":["EK\\u00D6P-24-4-SZTE-368"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["K143549"],"award-info":[{"award-number":["K143549"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["FK134863"],"award-info":[{"award-number":["FK134863"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cgh.2025.06.049","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:21:12Z","timestamp":1757517672000},"page":"1950-1959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis"],"prefix":"10.1016","volume":"24","author":[{"given":"Bernadett","family":"Farkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Res\u00e1l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy K.","family":"Limdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo V.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Michalopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Attauabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Benedict","family":"Seidelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios S.","family":"Fousekis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Bacsur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"B\u00e1lint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Iv\u00e1ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szepes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.06.049_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1381612825666190405141410","article-title":"JAK inhibition: the most promising agents in the IBD pipeline?","volume":"25","author":"Fern\u00e1ndez-Clotet","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cgh.2025.06.049_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101866","article-title":"Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"57","author":"Attauabi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cgh.2025.06.049_bib3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.06.049_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2025.06.049_bib5","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.06.049_bib6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.06.049_bib7","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.06.049_bib8","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.3390\/jcm13247804","article-title":"Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn\u2019s disease: a retrospective, multicentre study","volume":"13","author":"Farkas","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cgh.2025.06.049_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD Research Consortium multicenter national cohort study","volume":"118","author":"Ma","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.06.049_bib10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.14309\/ajg.0000000000002145","article-title":"Real-world evidence of tofacinitib in ulcerative colitis: short-term and long-term effectiveness and safety","volume":"118","author":"Chaparro","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.06.049_bib11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Massachusetts General Hospital Crohn\u2019s And Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.06.049_bib12","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.14309\/ajg.0000000000002746","article-title":"One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: a multicenter cohort study","volume":"119","author":"Dalal","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.06.049_bib13","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.14309\/ajg.0000000000002947","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in ulcerative colitis: a U.S. propensity-matched cohort study","volume":"119","author":"Kochhar","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.06.049_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.06.049_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.06.049_bib16","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s10620-024-08630-3","article-title":"Response to upadacitinib in patients with inflammatory bowel disease previously treated with tofacitinib","volume":"69","author":"Odah","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2025.06.049_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/apt.17248","article-title":"Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry","volume":"57","author":"Straatmijer","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.06.049_bib18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15689","article-title":"Dutch Initiative on Crohn and Colitis (ICC). Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.06.049_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Initiative on Crohn and Colitis. Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide Dutch registry study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.06.049_bib20","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.06.049_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.06.049_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652500761X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652500761X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:35:37Z","timestamp":1782200137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652500761X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S154235652500761X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.06.049","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upadacitinib Is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-Severe Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.06.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Gastroenterological Association Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}